Novo Nordisk South Africa will release a lower-cost, authorized version of semaglutide. This move is specifically targeted at increasing access to the medication for individuals with type 2 diabetes. Currently, semaglutide has gained attention as a weight-loss drug, driving up demand and costs. The new version aims to address affordability barriers for those who require it for its primary purpose: diabetes management. The company hopes this will significantly improve treatment options for a larger segment of the South African population. This launch prioritizes medical need over the lifestyle weight-loss trend. Further details regarding pricing and availability will be announced soon.